ABC | Volume 113, Nº4, October 2019

Updated Updated Cardiovascular Prevention Guideline of the Brazilian Society Of Cardiology – 2019 Arq Bras Cardiol. 2019; 113(4):787-891 men: the Physicians' Health Study II randomized controlled trial. JAMA. 2008;300(18):2123-33. 210. Lee CH, Chan RSM, Wan HYL, Woo YC, Cheung CYY, Fong CHY, et al. Dietary intake of anti-oxidant vitamins A, C, and E Is inversely associated with adverse cardiovascular outcomes in Chinese-A 22-years population- based prospective study. Nutrients. 2018;10(11):pii:E1664. 211. MichosED,BlumenthalRS.VitaminDsupplementationandcardiovascular disease risk. Circulation. 2007;115(7):827-8. 212. Zittermann A, Gummert JF, Borgermann J. The role of vitamin D in dyslipidemia and cardiovascular disease. Curr Pharm Des. 2011;17(9):933-42. 213. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503-11. 214. Zittermann A, Borgermann J, Gummert JF, Pilz S. Future directions in vitamin D and cardiovascular research. Nutr Metab Cardiovasc Dis. 2012;22(7):541-6. 215. Beveridge LA, Khan F, Struthers AD, Armitage J, Barchetta I, Bressendorff I, et al. Effect of vitaminD supplementation onmarkers of vascular function: a systematic review and individual participant meta-analysis. J Am Heart Assoc. 2018;7(11):pii:e008273. 216. Manson JE, CookNR, Lee IM, ChristenW, Bassuk SS, Mora S, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33-44. 217. Scragg R, Stewart AW, Waayer D, Lawes CMM, Toop L, Sluyter J, et al. Effect of monthly high-dose vitamin d supplementation on cardiovascular disease in the vitamin D assessment study: a randomized clinical trial. JAMA Cardiol. 2017;2(6):608-16. 218. Hiemstra T, LimK, Thadhani R, Manson JE. VitaminD and atherosclerotic cardiovascular disease. J Clin Endocrinol Metab. 2019 Apr 4;pii:jc.2019-00194. 219. Hartley L, Clar C, Ghannam O, Flowers N, Stranges S, Rees K. Vitamin K for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2015 Sep 21;(9):CD011148. 220. VermaH, Garg R. Effect of vitamin K supplementation on cardiometabolic risk factors: a systematic reviewandmeta-analysis. EndocrMetab Immune Disord Drug Targets. 2019;19(1):13-25. 221. Kubota Y, Iso H, Date C, Kikuchi S, Watanabe Y, Wada Y, et al. Dietary intakes of antioxidant vitamins and mortality from cardiovascular disease: the Japan Collaborative Cohort Study (JACC) study. Stroke. 2011;42(6):1665-72. 222. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2012 Mar 14; (3):CD007176. 223. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: ameta-analysis. JAMA. 2002;288(16):2015-22. 224. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA. 2006;296(22):2720-6. 225. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serummarkers of cardiovascular disease risk: a systematic review. Atherosclerosis. 2006;189(1):19-30. 226. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infartomiocardico. Dietary supplementationwith n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of theGISSI-Prevenzione trial. Lancet. 1999;354(9177):447-55. 227. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090-8. 228. Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363(21):2015-26. 229. Risk and Prevention Study CollaborativeGroup, Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800-8. 230. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002;20(8):1493-9. 231. Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of Omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol. 2018;3(3):225-34. 232. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018 Nov 30;11:CD003177. 233. Manson JE, Cook NR, Lee IM, ChristenW, Bassuk SS, Mora S, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. NEngl J Med. 2019;380(1):23-32. 234. ASCENDStudyCollaborativeGroup,BowmanL,MafhamM,Wallendszus K, Stevens W, Buck G, et al. Effects of n-3 Fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540-50. 235. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo- controlled trial. Lancet. 2008;372(9645):1223-30. 236. Wendland E, Farmer A, Glasziou P, Neil A. Effect of alpha linolenic acid on cardiovascularr iskmarkers:asystematicreview.Heart. 2006;92(2):166-9. 237. Prasad K. Flaxseed and cardiovascular health. J Cardiovasc Pharmacol. 2009;54(5):369-77. 238. Pan A, Chen M, Chowdhury R, Wu JH, Sun Q, Campos H, et al. alpha- Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr. 2012;96(6):1262-73. 239. Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Analise em Saude e Vigilancia de Doencas nao Transmissiveis. Vigitel Brasil 2018: vigilancia de fatores de risco e proteço para doencas cronicas por inquerito telefonico: sobre tabagismo. Brasilia: Ministerio da Saude, 2019. 240. Tanrikulu MA, Agirbasli M, Berenson G. Primordial prevention of cardiometabolic risk in childhood. Cham: Springer; 2016.p.489-96. (Advances In Experimental Medicine And Biology). 241. Duncan LR, Pearson ES, Maddison R. Smoking prevention in children and adolescents: a systematic review of individualized interventions. Patient Educ Couns. 2018;101(3):375-88. 242. DuncanLR,BertoliMC,Latimer-CheungAE,RiversSE,BrackettMA,Salovey P.Mappingtheprotectivepathwayofemotional intelligence inyouth:From social cognition to smoking intentions. Pers IndividDif. 2013;54(4):542-4. 243. Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med. 2006;31(1):52-61. 244. DiFranza JR, Savageau JA, Fletcher K, O'Loughlin J, Pbert L, Ockene JK, et al. Symptoms of tobacco dependence after brief intermittent use: the Development and Assessment of Nicotine Dependence in Youth-2 study. Arch Pediatr Adolesc Med. 2007;161(7):704-10. 245. US Departmente of Health & Human Services [Internet]. Surgeon General's Report: Preventing TobaccoUse Among Youth and Young Adults [Cited in 2019 may 21]. Available from: https://www.cdc.gov/. 246. Pierce JP, Choi WS, Gilpin EA, Farkas AJ, Merritt RK. Validation of susceptibility as a predictor of which adolescents take up smoking in the United States. Health Psychol. 1996;15(5):355-61. 875